FTII invests in Med BioGene Inc.

Fundamental Technologies II Corp. (FT II) is pleased to announce it has added to its portfolio of emerging technology companies with an investment in Med BioGene Inc., a publicly held Vancouver-based "life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic and prognostic tests for cancer and cardiovascular disease.

MBI develops these tests by identifying the genes, known as "biomarkers," which indicate the presence of disease. The development of these tests is the first step towards personalized medicine and will assist in replacing the conventional "one drug fits all" approach to disease management."

The expected benefits of these tests are:

• "Improved Diagnostics: MBI's tests are expected to provide more accurate, objective and quicker diagnosis, allowing healthcare providers to deliver more appropriate and timely care to patients."
• "Personalized Treatment: MBI's tests outline a patient's genetic profile and may assist doctors in tailoring treatment decisions to the needs of each patient, thus making treatment more effective and reducing healthcare costs by minimizing the treatment of non-responders."
• "Therapeutic Development: Pharmaceutical companies can prioritze MBI's genomic biomarkers for use as potential therapeutic targets and to validate the effectiveness of specific therapeutics."

"MBI's lead products are LungExpress Dx™, a gene expression-based prognostic test for lung cancer, and LymphExpress Dx™, a gene expression-based diagnostic and prognostic test for lymphoma."

In a recent news release, Erinn Broshko, MBI’s Chief Executive Officer, stated "Med BioGene has made tremendous progress over the last quarter. On the business front, we closed the first tranche of our public offering in extremely difficult financial markets and expect to close our second and final tranche in the beginning of September. With these funds, we are planning to begin in 2009 commercialization in the United States of LungExpress Dx™, the world’s first gene expression-based prognostic test for lung cancer." Broshko added "the last quarter of 2008 will be extremely exciting for us as we prepare for the launch of our commercial operations."

Med BioGene is the sixth position added to the FT II portfolio since inception in June of 2005.

Read more about Med BioGene on their website at www.medbiogene.com.